高感度TSH-RIAのルチン使用経験
スポンサーリンク
概要
- 論文の詳細を見る
Forty-one routine TSH assays were carried out by applying newly developed, highly sensitive TSH RIA (T. Mori, et al., Folia Endocrinol. Jap., 56 : 1231, 1980).<BR>B/B<SUB>0</SUB> percent of the least standard point (0.156μU/ml) was consistently lower than B<SUB>0</SUB> and higher than that of 0.31μU/ml.<BR>The distributions of assayed TSH concentrations in 1394 sera revealed that 34.8% of the total were in an undetectable range when measured by conventional method ( < 1.0μU/ml), but this method picked up 16.4% (0.156-1.0μU/ml), and only 5.4% exceeded the upper limit (20μU/ml).<BR>TRH test results (500μg i.v. bolus) in 45 cases of thyroid disorders with low or normal basal TSH revealed that the peak TSH of those with basal TSH of 0.156-1.0μU/ml (8.98 ± 4.15μU/ml) was significantly different from those of less than 0.156μU/ml or 1.0-3.2μU/ml.<BR>Further, TSH concentrations in 19 patients after T3 administration (75μg × 7 days) were 0.183 ± 0.073μU/ml, and all but one (0.43μU/ml) showed values lower than the normal range (0.31-3.2μU/ml).<BR>Thyroid hormone concentrations in cases with TSH of 0.156-1.0μU/ml were limited in the ranges of less than 300 ng/dl T3 and/or less than 15μg/dl T4, and these were considered to be the threshold of definite TSH inhibition. TSH concentrations of less than 0.31μU/ml were generally associated with clinical conditions or laboratory findings of decreased TSH secretion, although there were a few cases showing undetectable TSH with normal or low T4 and T3.<BR>In conclusion, this highly sensitive TSH RIA could detect 76.2% of serum TSH in various thyroid states, and detection of a lower TSH range was found quite meaningful. Routine application of this assay should be strongly recommended.
- 日本内分泌学会の論文
著者
-
石原 隆
神戸市立医療センター中央市民病院糖尿病内分泌内科
-
森 徹
武田病院 内科
-
尾藤 早苗
神戸市立中央市民病院核医学科
-
池窪 勝治
神戸市立中央市民病院 核医学科
-
石原 隆
神戸市立中央市民病院
-
森 徹
神戸市立中央市民病院
-
石原 隆
神戸市立中央市民病院 内科
関連論文
- 症例報告 シタグリプチンをグリメピリドに追加投与し,3日後に重症低血糖症を起こした2型糖尿病の1例
- ^In-DTPA-D-Phe-octreotideの消化管ホルモン産生腫瘍を対象とした第III相臨床試験
- ヒト4型メラノコルチン受容体(MC4R)の新規遺伝子異常により発症した肥満症
- Macroadenoma の術前検査にホルモン刺激試験は必要か : 刺激試験により下垂体卒中を誘発した2症例の検討
- 異所性ACTH産生を伴った褐色細胞腫の1例
- 薬剤性低血糖による意識障害で救急受診した2型糖尿病患者50例の検討
- 副腎不全を呈した血管内リンパ腫の一例
- プロラクチン自己抗体により高プロラクチン血症を呈した症例に関する検討
- 発症前からの自己抗体の変動をとらえた慢性C型肝炎インターフェロン治療中に1型糖尿病および甲状腺機能低下症を発症した1症例
- TRH(Thyrotropin releasing hormone)遺伝子シグナルペプチド領域にSNP(single nucleotide polymorphism)を認めた視床下部性甲状腺機能低下症の1例